Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_assertion description "[ETA R antagonism with atrasentan reduced cell proliferation by 16% in papillary carcinoma cells (P < 0.05) and by 51% in follicular carcinoma cells (P < 0.001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_assertion evidence source_evidence_literature NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_assertion SIO_000772 17561979 NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_assertion wasDerivedFrom befree-2016 NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_assertion wasGeneratedBy ECO_0000203 NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.
- befree-2016 importedOn "2016-02-19" NP614602.RAcYS1DjBqN4LDPgn66Mk6s5pFqXmb78tnd_cZ2tu7LbQ130_provenance.